NCT00595686已完成1 期
A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Esanex Inc.
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- adverse events and other safety assessments
研究概览
简要总结
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>18 years old
- •Karnofsky performance status > 60
- •confirmed hematological malignancy
- •refractory to available therapy or for which no therapy is available
- •adequate hepatic, renal and hematological function
排除标准
- •CNS malignancy
- •at risk for prolonged QT interval
- •significant GI/liver disease
- •other serious concurrent illness or medical condition
研究组 & 干预措施
Single Arm
Experimental
干预措施: SNX-5422 (Drug)
结局指标
主要结局
adverse events and other safety assessments
时间窗: continuous
次要结局
- disease response specific to the hematological malignancy(after every 2 cycles)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor MalignanciesCancerNCT00506805Esanex Inc.44
已完成
1 期
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological MalignanciesCancerNCT01635712Esanex Inc.10
已完成
1 期
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor MalignanciesCancerNCT01611623Esanex Inc.9
终止
1 期
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive CancersCancerNCT01848756Esanex Inc.15
已完成
1 期
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid TumorsCancerNCT01892046Esanex Inc.18